Impact of Primary Pegfilgrastim Prophylaxis on Relative Dose Intensity in Neoadjuvant/Adjuvant FEC-100 Chemotherapy

This study aimed was to clarify the impact of pegfilgrastim (PEG) 3.6 mg primary prophylaxis of febrile neutropenia (FN) on the average relative dose intensity (ARDI) of neoadjuvant/adjuvant FEC-100 for breast cancer. This retrospective, single-centre cohort study including 296 patients who received...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2020-02, Vol.40 (2), p.915-921
Main Authors: Yokokawa, Takashi, Suzuki, Kenichi, Sugisaki, Takahito, Kobayashi, Kazuo, Shouji, Daigo, Watanabe, Hiroshi, Kawakami, Kazuyoshi, Takiguchi, Tomomi, Aoyama, Takeshi, Kobayashi, Kokoro, Takahashi, Shunji, Ito, Yoshinori, Ohno, Shinji, Hama, Toshihiro
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - pharmacology
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Breast cancer
Chemotherapy
Cohort Studies
Cyclophosphamide - pharmacology
Cyclophosphamide - therapeutic use
Drug dosages
Epirubicin - pharmacology
Epirubicin - therapeutic use
Female
Filgrastim - pharmacology
Filgrastim - therapeutic use
Fluorouracil - pharmacology
Fluorouracil - therapeutic use
Humans
Male
Middle Aged
Neoadjuvant Therapy - methods
Neutropenia
Polyethylene Glycols - pharmacology
Polyethylene Glycols - therapeutic use
Prophylaxis
Retrospective Studies
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aimed was to clarify the impact of pegfilgrastim (PEG) 3.6 mg primary prophylaxis of febrile neutropenia (FN) on the average relative dose intensity (ARDI) of neoadjuvant/adjuvant FEC-100 for breast cancer. This retrospective, single-centre cohort study including 296 patients who received FEC-100 compared PEG and non-PEG groups. The PEG group received PEG 3.6 mg as a single subcutaneous injection in each study cycle. The primary endpoint was the ARDI of FEC-100. The secondary endpoints were patient percentage of ARDI≥85%, factors associated with ARDI≥85%, and reasons for reduced ARDI. The PEG group showed significantly higher mean ARDI (95.6% versus 90.7%, p
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.14024